JTCS Tips for Better Browsing
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
John B. Chambers
Christopher I. Blauth
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chambers, J. B.
Right arrow Articles by Blauth, C. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chambers, J. B.
Right arrow Articles by Blauth, C. I.
Related Collections
Right arrow Valve disease

J Thorac Cardiovasc Surg 2006;131:878-882
© 2006 The American Association for Thoracic Surgery


Surgery for Acquired Cardiovascular Disease

The subcoronary Toronto stentless versus supra-annular Perimount stented replacement aortic valve: Early clinical and hemodynamic results of a randomized comparison in 160 patients

John B. Chambers, MD, FACC * , Helen M. Rimington, BSc, Fiona Hodson, RGN, Ronak Rajani, MRCP, Christopher I. Blauth, MS, FRCS

Valve Study Group, St Thomas Hospital, London, United Kingdom.

Received for publication August 1, 2005; revisions received November 14, 2005; accepted for publication November 18, 2005.

* Address for reprints: John Chambers, MD, FACC, Cardiothoracic Centre, St Thomas Hospital, London SE1 7EH, United Kingdom (Email: jboydchambers{at}aol.com).

BACKGROUND: A stentless valve is expected to be hemodynamically superior to a stented valve. The aim of this study was to compare early postoperative hemodynamic function and clinical events in a randomized, prospective series of 160 stentless and stented biological replacement aortic valves.

METHODS: We randomized 160 consecutive patients on 1 surgeon's list to receive either a Toronto stentless porcine valve (St Jude Medical, Inc, St Paul, Minn) or a Perimount stented bovine pericardial valve (Edwards Lifesciences, Irvine, Calif). Echocardiography was performed at discharge, between 3 and 6 months, and at 1 year after surgery. Statistical analysis was performed by both intention to treat and actual valves implanted.

RESULTS: The mean labeled size of both designs of valve was 24.7. There were no statistically significant differences in results at any time interval or whether analysis was performed by actual valves implanted or intention to treat. At 3 to 6 months for the Toronto versus the Perimount valve, the effective orifice area was 1.58 versus 1.66 cm2, the mean pressure difference was 7.54 versus 7.42 mm Hg, and the peak velocity was 2.07 versus 2.0.1 m/s. There was no difference in mortality, regression of left ventricular hypertrophy, or complications other than paraprosthetic regurgitation at 12 months or on follow-up for a proportion of the sample to 8 years. The incidence of regurgitation through the valves was similar for Toronto (10%) and Perimount (13.8%) at 1 year, but mild paraprosthetic regurgitation was found in 5 patients with the Perimount valve and none with Toronto valves.

CONCLUSIONS: There were no significant differences in hemodynamic function or clinical events between the stented and stentless biological valves chosen for comparison in the early postoperative period or in preliminary follow-up to 5 years.



Abbreviation and Acronym LV = left ventricular





This article has been cited by other articles:


Home page
Card Surg AdultHome page
R. F. Padera Jr. and F. J. Schoen
Pathology of Cardiac Surgery
Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178.
[Full Text]


Home page
ICVTSHome page
A. Kallikourdis and S. Jacob
Is a stentless aortic valve superior to conventional bioprosthetic valves for aortic valve replacement?
Interactive CardioVascular and Thoracic Surgery, October 1, 2007; 6(5): 665 - 672.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. D'Onofrio, S. Auriemma, P. Magagna, A. Favaro, A. Cannarella, C. Piccin, M. Bilotta, N. Abbiate, N. Lamascese, and A. Fabbri
Aortic valve replacement with the Sorin Pericarbon Freedom stentless prosthesis: 7 years' experience in 130 patients
J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 491 - 495.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
J. B. Chambers, H. M. Rimington, R. Rajani, F. Hodson, and F. Shabbo
A randomized comparison of the Cryolife O'Brien and Toronto stentless replacement aortic valves
J. Thorac. Cardiovasc. Surg., April 1, 2007; 133(4): 1045 - 1050.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. H. Rahimtoola
The Year in Valvular Heart Disease
J. Am. Coll. Cardiol., January 23, 2007; 49(3): 361 - 374.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
T. Bove, Y. Van Belleghem, K. Francois, F. Caes, H. Van Overbeke, and G. Van Nooten
Stentless and stented aortic valve replacement in elderly patients: factors affecting midterm clinical and hemodynamical outcome
Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 706 - 713.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. J. Antunes
Editorial comment: Aortic stenosis in the elderly: rethinking strategies
Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 713 - 715.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The American Association for Thoracic Surgery.